Cargando…

Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model

OBJECTIVES: Excessive consumption of added sugars in the human diet has been associated with obesity, type 2 diabetes (T2D), coronary heart disease (CHD) and other elements of the metabolic syndrome. Recent studies have shown that non-alcoholic fatty liver disease (NAFLD) is a critical pathway to me...

Descripción completa

Detalles Bibliográficos
Autores principales: Vreman, Rick A, Goodell, Alex J, Rodriguez, Luis A, Porco, Travis C, Lustig, Robert H, Kahn, James G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577881/
https://www.ncbi.nlm.nih.gov/pubmed/28775179
http://dx.doi.org/10.1136/bmjopen-2016-013543
_version_ 1783260432115433472
author Vreman, Rick A
Goodell, Alex J
Rodriguez, Luis A
Porco, Travis C
Lustig, Robert H
Kahn, James G
author_facet Vreman, Rick A
Goodell, Alex J
Rodriguez, Luis A
Porco, Travis C
Lustig, Robert H
Kahn, James G
author_sort Vreman, Rick A
collection PubMed
description OBJECTIVES: Excessive consumption of added sugars in the human diet has been associated with obesity, type 2 diabetes (T2D), coronary heart disease (CHD) and other elements of the metabolic syndrome. Recent studies have shown that non-alcoholic fatty liver disease (NAFLD) is a critical pathway to metabolic syndrome. This model assesses the health and economic benefits of interventions aimed at reducing intake of added sugars. METHODS: Using data from US National Health Surveys and current literature, we simulated an open cohort, for the period 2015–2035. We constructed a microsimulation model with Markov chains for NAFLD (including steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC)), body mass index, T2D and CHD. We assessed reductions in population disease prevalence, disease-attributable disability-adjusted life years (DALYs) and costs, with interventions that reduce added sugars consumption by either 20% or 50%. FINDINGS: The model estimated that a 20% reduction in added sugars intake will reduce prevalence of hepatic steatosis, NASH, cirrhosis, HCC, obesity, T2D and CHD. Incidence of T2D and CHD would be expected to decrease by 19.9 (95% CI 12.8 to 27.0) and 9.4 (95% CI 3.1 to 15.8) cases per 100 000 people after 20 years, respectively. A 20% reduction in consumption is also projected to annually avert 0.767 million (M) DALYs (95% CI 0.757M to 0.777M) and a total of US$10.3 billion (B) (95% CI 10.2B to 10.4B) in discounted direct medical costs by 2035. These effects increased proportionally when added sugars intake were reduced by 50%. CONCLUSIONS: The decrease in incidence and prevalence of disease is similar to results in other models, but averted costs and DALYs were higher, mainly due to inclusion of NAFLD and CHD. The model suggests that efforts to reduce consumption of added sugars may result in significant public health and economic benefits.
format Online
Article
Text
id pubmed-5577881
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55778812017-09-08 Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model Vreman, Rick A Goodell, Alex J Rodriguez, Luis A Porco, Travis C Lustig, Robert H Kahn, James G BMJ Open Public Health OBJECTIVES: Excessive consumption of added sugars in the human diet has been associated with obesity, type 2 diabetes (T2D), coronary heart disease (CHD) and other elements of the metabolic syndrome. Recent studies have shown that non-alcoholic fatty liver disease (NAFLD) is a critical pathway to metabolic syndrome. This model assesses the health and economic benefits of interventions aimed at reducing intake of added sugars. METHODS: Using data from US National Health Surveys and current literature, we simulated an open cohort, for the period 2015–2035. We constructed a microsimulation model with Markov chains for NAFLD (including steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC)), body mass index, T2D and CHD. We assessed reductions in population disease prevalence, disease-attributable disability-adjusted life years (DALYs) and costs, with interventions that reduce added sugars consumption by either 20% or 50%. FINDINGS: The model estimated that a 20% reduction in added sugars intake will reduce prevalence of hepatic steatosis, NASH, cirrhosis, HCC, obesity, T2D and CHD. Incidence of T2D and CHD would be expected to decrease by 19.9 (95% CI 12.8 to 27.0) and 9.4 (95% CI 3.1 to 15.8) cases per 100 000 people after 20 years, respectively. A 20% reduction in consumption is also projected to annually avert 0.767 million (M) DALYs (95% CI 0.757M to 0.777M) and a total of US$10.3 billion (B) (95% CI 10.2B to 10.4B) in discounted direct medical costs by 2035. These effects increased proportionally when added sugars intake were reduced by 50%. CONCLUSIONS: The decrease in incidence and prevalence of disease is similar to results in other models, but averted costs and DALYs were higher, mainly due to inclusion of NAFLD and CHD. The model suggests that efforts to reduce consumption of added sugars may result in significant public health and economic benefits. BMJ Publishing Group 2017-08-03 /pmc/articles/PMC5577881/ /pubmed/28775179 http://dx.doi.org/10.1136/bmjopen-2016-013543 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Public Health
Vreman, Rick A
Goodell, Alex J
Rodriguez, Luis A
Porco, Travis C
Lustig, Robert H
Kahn, James G
Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title_full Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title_fullStr Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title_full_unstemmed Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title_short Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
title_sort health and economic benefits of reducing sugar intake in the usa, including effects via non-alcoholic fatty liver disease: a microsimulation model
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577881/
https://www.ncbi.nlm.nih.gov/pubmed/28775179
http://dx.doi.org/10.1136/bmjopen-2016-013543
work_keys_str_mv AT vremanricka healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel
AT goodellalexj healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel
AT rodriguezluisa healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel
AT porcotravisc healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel
AT lustigroberth healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel
AT kahnjamesg healthandeconomicbenefitsofreducingsugarintakeintheusaincludingeffectsvianonalcoholicfattyliverdiseaseamicrosimulationmodel